Boehringer Shoots For Schizophrenia With PDE9 Inhibitor, Ends Alzheimer's R&D

 
• By Lucie Ellis-Taitt

Boehringer's investigational drug, BI 409306, is the second big pharma PDE9 inhibitor to fail in Alzheimer's clinical trials; Eisai is still standing with a Phase I compound but the odds are not in its favor.

Fork in the road
Boehringer takes a different path with pipeline drug after Alzheimer's Phase II miss • Source: Shutterstock

More from Clinical Trials

More from R&D